Efficacy and Safety of RO4917523 as add-on therapy in patients with Major Depressive Disorder who have inadequate response to ongoing antidepressant medication

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-001436-33

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the efficacy of two fixed doses of RO4917523 compared to placebo over 6 weeks as adjunctive therapy in patients with MDD with inadequate response to ongoing antidepressant treatment. The change will be measured based on the mean change in the Montgomery Asberg Depression Rating Scale (MADRS) total score from baseline to end of treatment.


Critère d'inclusion

  • -Major Depressive Disorder (MDD)

Liens